Previous close | 5.97 |
Open | 5.95 |
Bid | 6.02 x 200 |
Ask | 6.07 x 100 |
Day's range | 5.76 - 6.08 |
52-week range | 3.45 - 10.83 |
Volume | |
Avg. volume | 334,546 |
Market cap | 263.976M |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 27 Jan 2010 |
1y target est | N/A |
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript May 5, 2024 AxoGen, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the AxoGen, Inc. 2024 First Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, […]
AxoGen ( NASDAQ:AXGN ) First Quarter 2024 Results Key Financial Results Revenue: US$41.4m (up 13% from 1Q 2023). Net...